NICE's Nod To Soliris Tainted By Request For R&D Cost Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.s NICE is on the verge of recommending Alexion's Soliris for aHUS despite an astronomic price; but its request for R&D cost data will alarm the drug industry.